Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature

CNS Drug Reviews

Volumn 10, Issue 1, 2004, Pages 45-76

  Verster, Joris C ^a   Volkerts, Edmund R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alprazolam; Anxiety; Benzodiazepines; Depression; Panic; Sedation

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; KETOCONAZOLE; NEFAZODONE; ONDANSETRON; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; AGORAPHOBIA; ANOREXIA; ANXIETY DISORDER; ATAXIA; BEHAVIOR; CHILDHOOD DISEASE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRIVING ABILITY; DROWSINESS; DRUG ABUSE; DRUG ALCOHOL INTERACTION; DRUG BINDING; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MALAISE; MEMORY DISORDER; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; PANIC; REVIEW; SEDATION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TACHYCARDIA; TASK PERFORMANCE; VISUAL IMPAIRMENT; VOMITING;

EID: 1642372087     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2004.tb00003.x     Document Type: Review

References (291)

1. Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 1983;80:275-278.
2. Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. Br J Clin Pharmacol 1985;19:51-57.
3. Achmin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effects of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998;34:211-219.
4. Aden GC, Thein SG. Alprazolam compared to diazepam and placebo in the treatment of anxiety. J Clin Psychiatry 1980;41:245-248.
5. Alexander PE. The need for extended-release medications. Curr Ther Res 1995;56:940-946.
6. Allen D, Curran HV, Lader M. The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects. Eur J Clin Pharmacol 1991;40:355-362.
7. American Psychiatric Association (APA). Practical guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998;155:1-34.
8. Anderson IM, Nutt DJ, Deakin FW. Evidence-based guideline for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14:3-20.
9. Ansseau M, Ansoms C, Beckers G, et al. Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. J Affect Disord 1984;7:287-296.
10. Aranko K, Mattila MJ, Bordignon D. Psychomotor effects of alprazolam and diazepam during acute and subacute treatment, and during the follow-up phase. Acta Pharmacol Toxicol 1985;56:364-372.
11. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-422.
12. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World Biol Psychiatry 2002;3:171-199.
13. Banerji JR, Brantingham P, McEwan GD, et al. A comparison of alprazolam with amitriptyline in the treatment of patients with neurotic or reactive depression. Irish J Med Sci 1989;158:110-113.
14. Barbee JG, Black FW, Kehoe CE, Todorov AA. A comparison of the single-dose effects of alprazolam, buspirone, and placebo upon memory function. J Clin Psychopharmacol 1991;11:351-356.
15. Barbee JG, Mancuso DM, Freed CR, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992;149:506-510.
16. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331-1336.
17. Berg F van den, Tulen JHM, Boomsma F, Noten JBGM, Moleman P, Pepplinkhuizen L. Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. Psychopharmacology 1996;128:21-30.
18. Berger CO, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: A double-blind, placebo-controlled crossover study. Obstet Gynecol 1994;84:379-385.
19. Bertolino A, Mastucci E, Porro V, et al. Etizolam in the treatment of generalized anxiety disorder: A controlled clinical trial. J Int Med Res 1989;17:455-460.
20. Bertz RJ, Kroboth PD, Kroboth FJ, et al. Alprazolam in young and elderly men: Sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther 1997;281:1317-1329.
21. Blackwell B. Compliance. Psychother Psychosomatics 1992;58:161-169.
22. Block RI, Berchou R. Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Pharmacol Biochem Behav 1984;20:233-241.
23. Blom MW, Bartel PR, de Sommers K, Van der Meyden CH, Becker PJ. The effects of alprazolam, quazepam and diazepam on saccadic eye movements, parameters of psychomotor function and the EEG Fund Clin Pharmacol 1990;4:653-661.
24. Bond A, Silveira JC, Lader M. Effects of single doses of alprazolam and alcohol alone and in combination on psychological performance. Hum Psychopharmacol 1991;6:219-228.
25. Bond AJ, Silveira JC, Lader MH. The effects of alprazolam alone and in combination with alcohol on central integrative activity. Eur J Clin Pharmacol 1992;42:495-498.
26. Bond AJ, Silveira JC. The combination of alprazolam and alcohol on behavioral aggression. J Stud Alcohol 1993;11(Suppl):30-39.
27. Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioural aggression in panic disorders after 8 weeks' treatment with alprazolam. J Affect Disord 1995;35:117-123.
28. Bourin M, Colombel M, Guitton B. Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers. J Clin Psychopharmacol 1998;18:364-372.
29. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis. Int Clin Psychopharmacol 1995;10:45-49.
30. Bramanti P, Ricci RM, Rifici C, et al. Etizolam: A controlled study versus alprazolam in the treatment of generalized anxiety disorder with minor associated depressive symptoms. Curr Ther Res 1990;48:369-377.
31. Brand N, Jolles J. Information procesing in depression and anxiety. Psychol Med 1987;17:97-105.
32. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51:236-238.
33. Bruce TJ, Spiegel DA, Gregg SF, Nuzzarello A. Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. Am J Psychiatry 1995;152:1156-1160.
34. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003;160:1432-8.
35. Buch AB, van Harken DR, Seidehamel RJ, Barbhaiya RH. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993;33:1104-1109.
36. Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: A meta-analysis of the association, its pattern, and specificity. Psychol Bull 1995;117:285-305.
37. Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994;55:451-463.
38. Busto UE, Kaplan HL, Wright CE, et al. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. J Clin Psychopharmacol 2000;20:628-635.
39. Cassano GB, Toni C, Petracca A, et al. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. Eur Neuropsychopharmacol 1994;4:47-53.
40. Castillo A, Sotillo C, Mariategui J. Alprazolam compared to clobazam and placebo in anxious outpatients. Neuropsychobiology 1987;18:189-194.
41. Češková E, Švestka K, Náhunek K, Obrovská V. Double blind comparison of alprazolam with dosulepine in endogenous depression. Activ Nerv Super 1989;31:290-291.
42. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-586.
43. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418-423.
44. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998;46:620-625.
45. Ciraulo DA, Antal EJ, Smith RB, et al. The relationship of alprazolam dose to steady-state plasma concentrations. J Clin Psychopharmacol 1990;10:27-32.
46. Ciraulo DA, Barnhill JG, Ciraulo AM, et al. Alternations in pharmacodynamics of anxiolytics in abstinent alcoholic men: Subjective reponses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Psychopharmacol 1997;37;64-73.
47. Ciraulo DA, Knapp CM, LoCastro J, Greenblatt DJ, Shader RI. A benzodiazepine mood effect scale: Reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. Am J Drug Alcohol Abuse 2001;27:339-347.
48. Clark DB, Taylor CB, Roth WT, et al. Surreptitious drug use by patients in a panic disorder study. Am J Psychiatry 1990;147:507-509.
49. Cohn JB. Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J Clin Psychiatry 1981;42:347-351.
50. Cohn JB, Wilcox CS. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy 1984;4:93-98.
51. Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double-blind study. J Clin Psychiatry 1986;47:409-412.
52. Coldwell SE, Milgrom P, Getz T, Ramsay DS. Amnestic and anxiolytic effects of alprazolam in oral surgery patients. J Oral Maxillofac Surg 1997;55:1061-1070.
53. Cox BJ, Endler N, Lee PS, Swinson RP. A meta-analysis of treatments for panic disorder with agoraphobia: Imipramine, alprazolam and in vivo exposure. J Behav Ther Exp Psychiatry 1992;23:175-182.
54. Crombez G, Kupers R, Adriaensen H. The effects of a single oral dose of lorazepam and alprazolam on reaction times in young healthy volunteers. Acta Anaesthesiol Belg 1991;42:79-84.
55. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191-202.
56. Curran HV. Benzodiazepines, memory and mood: A review. Psychopharmacology 1991;105:1-8.
57. Curran HV, Bond A, O'Sullivan G, et al. Memory functions, alprazolam and exposure therapy: A controlled longitudinal study of agoraphobia with panic disorder. Psychol Medicine 1994;24:969-976.
58. Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB. Maintenance drug therapy of panic disorder. J Psychiat Res 1993;27(Suppl 1):127-142.
59. A receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25:139-148.
60. Danjou P, Warot D, Hergueta T, Lacomblez L, Bouhours P, Puech AJ. Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: Some trait anxiety-independent responses. Int Clin Psychopharmacol 1992;7:73-79.
61. Davison K, Farquharson RG, Kahn MC, et al. A double-blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out-patients. Psychopharmacology 1983;80:308-310.
62. Davison K, Farquharson RG, Kahn MC, et al. A double-blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out-patients. Br J Clin Pharmacol 1985;19(Suppl 1):37S-43S.
63. Dehlin O, Kullingsjö H, Lidén A, Agrell B, Moser G, Olsen I. Pharmacokinetics of alprazolam in geriatric patients with neurotic depression. Pharmacol Toxicol 1991;68:121-124.
64. Diegoli MSC, da Fonseca AM, Diegoli CA, Pinotti JA. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynecol Obstet 1998;62:63-67.
65. Doble A. New insights into the mechanisms of action hypnotics. J Psychopharmacol 1999;13(Suppl 4): S11-S20.
66. Draper RJ, Daly I. Alprazolam and amitriptyline: A double blind comparison of anxiolytic and anti-depressant activity. Irish Med J 1983;76:453-456.
67. Dratcu L, Bond A. Panic patients in the non-panic state: Physiological and cognitive dysfunction. Eur Psychiatry 1998;3:18-25.
68. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effects of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. J Clin Psychiatry 1986;47:458-460.
69. DuPont RL, Swinson RP, Ballenger JC, et al. Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol 1992;12:352-354.
70. Edwards JG, Inman WHW, Pearce GL, Rawson NSB. Prescription-event monitoring of 10895 patients treated with alprazolam. Br J Psychiatry 1991;158:387-392.
71. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984;4:125-129.
72. Ellinwood EH, Heatherly DG, Nikaido AM, Bjomsson TD, Kilts C. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 1985;86:392-399.
73. Ellinwood EH, Nikaido AM, Heatherly DG, Bjornsson TD. Benzodiazepine pharmacodynamics: Evidence for biophase rate limiting mechanisms. Psychopharmacology 1987;91:168-174.
74. Ellinwood EH, Nikaido AM, Gupta SK, Heatherly DG, Hege S. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. J Psychopharmacol 1993;7:24-32.
75. Enkelman R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991;105:428-432.
76. Eriksson B, Nagy A, Starmark J-E, Thelander U. Alprazolam compared to amitriptyline in the treatment of major depression. Acta Psychiatr Scand 1987;75:656-663.
77. Evans SM, Troisi JR, Griffiths RR. Tandospirone and alprazolam: Comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 1994;271:683-694.
78. Evans SM, Foltin RW, Levin FR, Fischman MW. Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 1995;6:176-186.
79. Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW. Mood and performance changes in women with premenstrual dysphoric disorder: Acute effects of alprazolam. Neuropsychopharmacology 1998;19: 499-516.
80. Evans SM, Foltin RW, Fischman MW. Food "cravings" and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999;32:331-349.
81. Evans SM, Levin FR, Fischman MW. Increased sensitivity to alprazolam in females with a paternal history of alcoholism. Psychopharmacology 2000;150:150-162.
82. Evans SM, Levin FR. The effects of alprazolam and buspirone in light and moderate female social drinkers. Behav Pharmacol 2002;13:427-439.
83. Fabre LF, McLendon D. Alprazolam efficacy in anxiety. Clin Pharmacol Ther 1979;25:233.
84. Farbe LF, McLendon DM. A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Ther Res 1980;27:474-482.
85. Fawcett J, Kravitz HM, Howard HM, Jeffriess H. Alprazolam: An antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopharmacol 1987;7:295-310.
86. Feighner JP, Aden GC, Farbe LF, Rickels K, Smith WT. Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 1983;249:3057-3064.
87. Feighner JP, Meredith CH, Frost NR, Chammas S, Hendrickson G. A double-blind comparison of alprazolam vs. imipramine and placebo in the treatment of major depressive disorder. Acta Psychiatr Scand 1983; 68:223-233.
88. Ferguson HB, Simeon JG. Evaluating drug effects on children's cognitive functioning. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:683-686.
89. Fernandez-Guardiola A, Jurado JL, Aguilar-Jimenez E. Evaluation of the attention and sleepiness states by means of a psychophysiological test of reaction time and time estimate in man: Effects of psychotropic drugs. Curr Ther Res 1984;35:1000-1009.
90. Fleishaker JC, Phillips JP, Eller MG, Smith RB. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation. J Clin Pharmacol 1989;29: 543-549.
91. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-39.
92. Fleishaker JC, Garzone PD, Chambers JH, Sirocco K, Weingartner H. Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Psychopharmacology 1995;120:169-176.
93. Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999;156:1403-1408.
94. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-57.
95. Friedman MJ, Stolk JM, Harris PQ, et al. Serum dopamine-β -hydroxylase activity in depression and anxiety. Biol Psychiatry 1984;19:557-570.
96. Fujita M, Woods SW, Verhoef NPLG, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol 1999;368:161-172.
97. Furukori H, Otani K, Yasui N, et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 1998;18:364-369.
98. Gaillard AWK. The evaluation of drug effects in laboratory tasks. In: Hindmarch I, Aufdembrinke B, Ott H, Eds. Psychopharmacology and Reaction Time. New York: Wiley Medical Publication, 1988.
99. Gelemter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48:938-945.
100. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: A review. Anesthesiology 1990;72: 926-938.
101. Gladsjo JA, Rapaport MH, McKinney R, et al. A neuropsychological study of panic disorder: Negative findings. J Affect Disord 1998;49:123-131.
102. Gladsjo JA, Rapaport MH, McKinney R, et al. Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J Clin Psychopharmacol 2001;21:131-138.
103. Goldberg SC, Ettigi P, Schulz PM, Hamer RM, Hayes PE, Friedel RO. Alprazolam versus imipramine in depressed out-patients with neurovegetative signs. J Affect Disord 1986;11:139-145.
104. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly. Arch Gen Psychiatry 1983;40:287-290.
105. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 1988;44:326-334.
106. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Clin Pharmacokinet 1991;21:165-177.
107. Greenblatt DJ, Preskom SH, Cotreau MM, Holst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486.
108. Greenblatt DJ, Wright E. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 1993;24:453-471.
109. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: Clinical implications. J Clin Psychiatry 1993;54(Suppl 10):4-11.
110. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam administrations. Relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:715-722.
111. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998;64:237-247.
112. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines. III A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15: 399-408.
113. Gunal DI, Afsar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: Double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci 2000;21:315-317.
114. Haney M, Foltin RW, Fischman MW. Behavioral contingencies modulate alprazolam self-administration by humans. Behav Pharmacol 1997;8:82-90.
115. Harrison WM, Endicott J, Nee J. Treatment of dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990;47:270-275.
116. Hart RP, Colenda CC, Hamer RM. Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects. Am J Psychiatry 1991;148:73-77.
117. Hayashi R. Correlation between coefficient of variation of choice reaction time and components of event-related potentials (P300): Effect of a benzodiazepine. J Neurol Sci 2000;178:52-56.
118. Hayoun H, Hirigoyen M-F, Prigent Y, et al. Double-blind, comparative, multicenter study of two benzodiazepines in 117 outpatients: Alprazolam versus clobazam. Psychiat Psychobiol 1987;2:202-213.
119. Hecquet S, Puech AJ, Lecrubier Y. Double-blind study, alprazolam versus lorazepam in ambulatory anxious patients. Therapie 1984;39:253-261.
120. Hindmarch I. Measuring the side-effects of psychoactive drugs: A pharmacodynamic profile of alprazolam. Alcohol Alcoholism 1983;18:361-367.
121. Hoehn-Saric R, McLoad DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301.
122. Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991;9: 1004-1011.
123. Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharmac Res 1997;14:309-315.
124. Hubain PP, Castro P, Mesters P, De Maertelaer V, Mendlewicz J. Alprazolam and amitriptyline in the treatment of major depresssive disorder: A double-blind clinical and sleep EEG study. J Affect Disord 1990;18:67-73.
125. Huynh L, Fields S. Alprazolam for tinnitus. Ann Pharmacother 1995;29:311-312.
126. Imlah NW. An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression. Br J Psychiatry 1985;146:515-519.
127. lqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39-49.
128. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993;119:842-845.
129. Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: A review of the literature. J Clin Psychiatry 1993;54 (Suppl 10):25-45.
130. Jonas JM, Hearron AE. Alprazolam and suicidal ideation: A meta-analysis of controlled trials in the treatment of depression. J Clin Psychopharmacol 1996;16:208-211.
131. Juhl RP, van Thiel DH, Dittert LW, Smith RB. Alprazolam pharmacokinetics in alcohol liver disease. J Clin Pharmacol 1984;24:113-119.
132. Jurado JL, Fernández-Mas R, Fernández-Guardiola A. Effects of 1 week administration of two benzodiazepines on the sleep and early daytime performance of normal subjects. Psychopharmacology 1989;99: 91-93.
133. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. J Clin Pharmacol 1997;38: 14-21.
134. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol 2000;20:338-346.
135. Katschnig H, Amering M, Stolk JM, et al. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 1995;167:487-494.
136. Katschnig H, Amerig M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996;32:149-155.
137. Kelly TH, Foltin RW, Serpick E, Fischman MW. Behavioral effects of alprazolam in humans. Behav Pharmacol 1997;8:47-57.
138. Kiliç C, Curran HV, Noshirvani H, Marks IM, Başoǧlu M. Long-term effects of alprazolam on memory: A 3.5 year follow-up of agoraphobia/panic patients. Psychol Med 1999;29:225-231.
139. Kindermann SS, Brown GG. Depression and memory in the elderly: A meta-analysis. J Clin Exp Neuropsychol 1997;19:625-642.
140. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 1991;50:404-409.
141. Kizilbash AH, Vanderploeg RD, Curtiss G. The effects of depression and anxiety on memory performance. Arch Clin Neuropsychol 2002;17:57-67.
142. Klerman GL. Overview of the cross-national collaborative panic study. Arch Gen Psychiatry 1988;45: 407-412.
143. Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavioral therapy in treatment of panic disorder. J Consult Clin Psychol 1990;58:77-84.
144. Koelega HS. Benzodiazepines and vigilance performance: A review. Psychopharmacology 1989;98: 145-156.
145. Kolin IS, Linet OI. Double-blind comparison of alprazolam and diazepam for subchronic withdrawal from alcohol. J Clin Psychiatry 1981;42:169-173.
146. Korzekwa MI, Steiner M. Assessment and treatment of premenstrual syndromes. Prim Care Update Obstet Gynecol 1999;6:153-162.
147. Kožená L, Frantik E, Horváth M. Vigilance impairment after a single dose of benzodiazepines. Psychopharmacology 1995;119:39-46.
148. Kožená L, Frantik E, Horváth M. Pharmacologically induced decrease in vigilance measured by two different psychological methods. Homeostasis 1997;38:64-65.
149. Kravitz HM, Fawcett J, Newman AJ. Alprazolam and depression: A review of risks and benefits. J Clin Psychiatry 1993;54(Suppl 10):78-84.
150. Kristjánsson F. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm Nord 1991;3:249-250.
151. Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther 1985;38:525-532.
152. Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: Psychomotor and EEG effects. Clin Pharmacol Ther 1988;43:270-277.
153. Kroboth PD, McAuley JW, Smith RB. Alprazolam in the elderly: Pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology 1990;100:477-484.
154. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines. I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995;15:306-319.
155. Kroboth PD, Folan MM, Bauer KS, Tullock W, Wright CE, Sweeney JA. Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course. J Clin Pharmacol 1998; 38:337-346.
156. Kumar R, Mac DS, Gabrielli WF, Goodwin DW. Anxiolytics and memory: A comparison of lorazepam and alprazolam. J Clin Psychiatry 1987;48:158-160.
157. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T, Lorkowski G. Treatment of depressive outpatients with lorazepam, alprazolam, amitriptyline and placebo. Psychopharmacology 1995;120: 109-115.
158. Laar van MW, Volkerts ER, Willigenburg van APP. Therapeutic effects and effects on actual driving performance on chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992;12:86-95.
159. Lappiere YD, Browne M, Oyewumi K, Sarantidis D. Alprazolam and amitriptyline in the treatment of moderate depression. Int Clin Psychopharmacol 1994;9:41-45.
160. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104:323-327.
161. Lenox RH, Shipley JE, Peyser JM, Williams JM, Weaver LA. Double-blind comparison of alprazolam versus imipramine in the inpatient treatment of major depressive illness. Psychopharmacol Bull 1984;20: 79-82.
162. Leon CA, DeArango MV, Arevallo W, et al. On treatment of panic disorder in Cali, Columbia: A comparison between alprazolam, and imipramine-administered samples, and a placebo-administered conirol group. Acta Psiquiatr Psicol Am Lat 1990;36:59-72.
163. Lepola U, Heikkinen H, Rimon R, Riekkinen P. Clinical evaluation of alprazolam in patients with panic disorder: A double-blind comparison with imipramine. Hum Psychopharmacol 1990;5:159-164.
164. Lepola UM, Rimon RH, Riekkinen PJ. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. Int Clin Psychopharmacol 1993;8:115-118.
165. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia: Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988;45:437-443.
166. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992;149:1556-1562.
167. Linnoila M, Stapleton JM, Lister R, et al. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol 1990;39:21-28.
168. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 1986;88:426-433.
169. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96-103.
170. Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. J Clin Psychiatry 1997;58 (Suppl 11):11-18.
171. Maletzky BM. Anxiolytic efficacy of alprazolam compared to diazepam and placebo. J Int Med Res 1980;8:139-143.
172. Marks IM, De Albuqueque A, Cottraux J, et al. The "efficacy" of alprazolam in panic disorder and agoraphobia: A critique of recent reports. Arch Gen Psychiatry 1989;46:668-672.
173. Marks IM, Swinson RP, Başoǧlu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Clin Psychiatry 1993;162:776-787,
174. Marks IM, Swinson RP, Başoǧlu M, et al. Reply to comment on the London/Toronto study. Br J Psychiatry 1993;162:790-794.
175. Marks IM, Başoǧlu M, Noshirvani H, Greist J, Swinson RP, O'Sullivan G. Drug treatment of panic disorder. Br J Psychiatry 1993;162:795-796.
176. McAuley JW, Friedman CI. Influence of endogenous progesterone on alprazolam pharmacodynamics. J Clin Psychopharmacol 1999;19:233-239.
177. McLendon DM, Fabre LF. A double-blind comparison of the efficacy of alprazolam, chlordiazepoxide hydrochloride and placebo in the chronic withdrawal period from alcohol. Curr Ther Res 1980;28:447-455.
178. McLoad DR, Hoehn-Saric R, Zimmerli WD, et al. Treatment effects of alprazolam and imipramine: Physiological v subjective changes in patients with generalized anxiety disorder. Biol Psychiatry 1990;28: 849-861.
179. Meco G, Capriani C, Bonifati U, et al. Etizolam: A new therapeutic possibility in the treatment of panic disorder. Advances in Therapy 1989;6:196-206.
180. Mendels J, Schless AP. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry 1986;47:357-361.
181. Möller H-J, Volz H-P, Reimann IW, Stoll K-D. Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001;21:59-65.
182. Mühlberg W, Rieck W, Arnold E, Ott G, Lungershausen E. Pharmacokinetics of alprazolam in elderly patients with multiple diseases. Arch Gerontol Geriatr 1997;25:91-100.
183. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 1995;57:356-366.
184. Mumford GK, Rush CR, Griffiths RR. Alprazolam and DN-2327 (Pazinaclone) in humans: Psychomotor, memory, subjective, and reinforcing effects. Exp Clin Psychopharmacol 1995;3:39-48.
185. Mumford GK, Rush CR, Griffiths RR. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 1995;272:570-580.
186. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propanolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989;9:22-27.
187. Münte TF, Gehde E, Johannes S, Seewald M, Heinze H. Effects of alprazolam and bromazepam on visual search and verbal recognition memory in humans: A study with event-related brain potentials. Neuropsychobiology 1996;34:49-56.
188. Nikaido AM, Ellinwood EH, Heatherly DG, Gupta SK. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology 1990;100:90-97.
189. Norman TR, Burrows GD, McIntyre IM. Pharmacokinetic and pharmacodynamic effects of a single nocturnal dose of alprazolam. Int Clin Psychopharmacol 1990;5:111-117.
190. Noyes R, DuPont RL, Pecknold JC, et al. Alprazolam in panic disorder and agopraphobia: Patient acceptance, side effects, and safety. Arch Gen Psychiatry 1988;45:423-428.
191. Noyes R, Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991;148:517-523.
192. Noyes R, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996;57:349-355.
193. O'Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982;217:79-81.
194. Oo CY, Kuhn RJ, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: Prediction of alprazolam transfer into milk. Br J Clin Pharmacol 1995;40:231-236.
195. O'Sullivan GH, Noshirvani H, Başoǧlu M, et al. Safety and side effects of alprazolam. Controlled study in agoraphobia with panic disorder. Br J Psychiatry 1994;165:79-86.
196. Oswald LM, Roache JD, Rhoades HM. Predictors of individual differences in alprazolam self-medication. Exp Clin Psychopharmacol 1999;7:379-390.
197. Otani K, Yasui N, Kaneko S, et al. Effects of genetically determined s-mephentoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology 1997;16:8-14.
198. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485-1490.
199. Overall JE, Donachie ND, Faillace LA. Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. J Clin Psychiatry 1987;48:51-54.
200. Pariante F, Cadeo S, Ecari U. Etizolam in the treatment of generalized anxiety disorder associated with depressive symptoms. Curr Med Res Opin 1989;11:543-549.
201. Pearlstein TP, Stone AB. Longterm fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332-335.
202. Pecknold JC, Swinson RP. Taper withdrawal studies with alprazolam in patients with panic disorder and agoraphobia. Psychopharmacol Bull 1986;22:173-176.
203. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: Discontinuation effects. Arch Gen Psychiatry 1988;45:429-436.
204. Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: Does GABA play a role in depression? Biol Psychiatry 1995;38:578-591.
205. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13: 257-263.
206. Pomara N, Tun H, DaSilva D, Hernando R, Deptula D, Greenblatt DJ. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: Relationship to duration of treatment and self-rated sedation. Psychopharmacol Bull 1998;34:139-153.
207. Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1985;23:447-451.
208. Pyke RE, Greenberg HS. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989;9:15-21.
209. Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ. A controlled study of alprazolam and propanolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol 1991;11:344-350.
210. Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JAE. A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients. Can J Psychiatry 1988;33:590-594.
211. Riba J, Rodriguez-Fornells A, Urbano G, Morte A, Antonijoan R, Barbanoj MJ. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: A dose response study. Psychopharmacology 2001;157:358-367.
212. Rickels K, Cohen D, Csanalosi I, Harris H, Koepke H, Werblowsky J. Alprazolam and imipramine in depressed outpatients: A controlled study. Curr Ther Res 1982;32:157-164.
213. Rickels K, Csanalosi I, Greisman P, et al. A controlled clinical trial of alprazolam for the treatment of anxiety. Am J Psychiatry 1983;140:82-85.
214. Rickels K, Schweizer E, Csanalosi I, Case W, Chung H. Long-term treatment of anxiety and risks of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45:444-450.
215. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61-68.
216. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998(Suppl 2):12S-18S.
217. Rickels K, Lucki I, Schweizer E, Garcia-Espana F, Case WG. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 1999; 19:107-113.
218. Rimon R, Kultalahti E-R, Kalli A, et al. Alprazolam and oxazepam in the treatment of anxious out-patients with depressive symptoms: A double-blind multicenter study. Pharmacopsychiatry 1991;24:81-84.
219. Rizley R, Kahn RJ, McNair DM, Frankenthaler BA. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull 1986;22:167-172.
220. Rohling ML, Green P, Allen III LM, Iverson GL. Depressive symptoms and neurocognitive test scores in patients pasing symptom validity tests. Arch Clin Neuropsychol 2002;17:205-222.
221. Romach MK, Busto UE, Sobell LC, Sobel MB, Somer GR, Sellers EM. Long-term alprazolam use: Abuse, dependence or treatment? Psychopharmacol Bull 1991;27:391-395.
222. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM. Characteristics of long-term alprazolam users in the community. J Clin Psychopharmacol 1992;12:316-321.
223. Romach M, Busto U, Somer G, Kaplan HL, Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry 1995;152:1161-1167.
224. 3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharmacol 1998;18:121-131.
225. Roy-Byrne P, Fleishaker J, Arnett C, et al. Effects of acute and chronic alprazolam treatment on cerebral blood flow, memory, sedation, and plasma catecholamines. Neuropsychopharmacology 1993;8:161-169.
226. A receptor subtypes: Dissecting their pharmacological functions. Trends Pharmacol Sci 2001;22:188-194.
227. Rush AJ, Erkman MK, Schlesser MA, et al. Alprazolam vs amitriptyline in depressions with reduced REM latencies. Arch Gen Psychiatry 1985;42:1154-1159.
228. Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp Clin Psychopharmacol 1997;5:28-38.
229. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. Arthr Rheum 1991;34:552-560.
230. Saletu B, Grünberger J, Linzmayer L, Semlitsch HV, Anderer P, Chwatal K. Pharmacokinetic and-dynamic studies with a new anxiolytic, suficlone, utilizing EEG mapping and psychometry. Br J Clin Pharmacol 1994;37:145-156.
231. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355-372.
232. Scavone JM, Greenblatt DJ, Shader RI. Alprazolam kinetics following sublingual and oral administration. J Clin Psychopharmacol 1987;7:332-334.
233. Scavone JM, Greenblatt DJ, Goddard JE, Friedman H, Harmatz JS, Shader RI. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. Eur J Clin Pharmacol 1992;42:439-443.
234. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993;50:467-473.
235. Schmith VD, Piraino, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. I. Pharmacokinetics. J Clin Pharmacol 1991;31:571-579.
236. Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. II. Pharmacodynamics. Clin Pharmacol Ther 1992;51:533-540.
237. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-93.
238. Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150:1210-1215.
239. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50:51-60.
240. Seidel WF, Cohen L, Wilson L, Dement WC. Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects. Psychopharmacology 1985;87:194-197.
241. Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry 1993;54(Suppl 10):64-75.
242. Semlitsch HV, Anderer P, Saletu B. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Eur J Clin Pharmacol 1995;49:183-191.
243. Sheehan DV, Coleman JH, Greenblatt DJ, et al. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 1984;4:66-75.
244. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: A double-blind placebo-controlled study. Acta Psychiatr Scand 1993;88:1-11.
245. Sheikh JI, Swales JI. Treatment of panic disorder in older adults: A pilot study comparison of alprazolam, imipramine and placebo. Int J Psychiatr Med 1999;29:107-117.
246. Shelton RC, Harvey DS, Stewart PM, Loosen PT. Alprazolam in panic disorder: A retrospective analysis. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:423-434.
247. Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992;31:29-33.
248. Simpson JJ, Davies WE. Recent advances in the pharmacological treatment of tinnitus. Trends Pharmacol Sci 1999;20:12-18.
249. Singh AN, Nair NPV, Suranyi-Cadotte B, Schwartz G, Lizondo E. A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depression. Can J Psychiatry 1988; 33:218-222.
250. Smith RB, Kroboth PD, Vanderlught JT, Philips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 1984;84:452-456.
251. Smith RB, Gwilt PR, Wright CE. Single and multiple dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharmacy 1983;2:139-143.
252. Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 1987;93:105-112.
253. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: Results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987;70:37-43.
254. Spiegel DA, Roth SM, Weissman M, Lavori P, Gorman J, Ballenger J. Comment on the London/Toronto study of alprazolam and exposure in panic disorder with agoraphobia. Br J Psychiatry 1993;162:788-789.
255. Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999;19:17S-22S.
256. Srisurapanont M, Boonyanaruthee V. Alprazolam and standard antidepressants in the treatment of depression: A meta-analysis of the antidepressant effect. J Med Ass Thai 1997;80:183-188.
257. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995;332:1529-1534.
258. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997;33:771-774.
259. Streeter CC, Ciraulo DA, Harris GJ, et al. Functional magnetic resonance imaging of alprazolam-induced changes in humans with familial alcoholism. Psychiatry Res Neuroimaging 1998;82:69-82.
260. Streufert S, Satish U, Pogash R, et al. Effects of alprazolam on complex human functioning. J Appl Soc Psychol 1996;26:1912-1930.
261. Subhan Z, Harrison Ch, Hindmarch I. Alprazolam and lorazepam. Single and multiple-dose effects on psychomotor skills and sleep. Eur J Clin Pharnmcol 1986;29:709-712.
262. Sumner DD. Benzodiazepine-induced persisting amnestic disorder: Are older adults at risk? Arch Psychiat Nursing 1998;12:119-125.
263. Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology 1995;121:442-450.
264. Swann AC, Katz MM, Bowden CL, Berman NG, Stokes PE. Psychomotor performance and monoamine function in bipolar and unipolar affective disorders. Biol Psychiatry 1999;45:979-988.
265. Taylor CB, Hayward C, King R, et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: Results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 1990;10:112-118.
266. Tesar GE, Rosenbaum JF, Pollach MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987;48(Suppl 10):16-19.
267. Tesar GE, Rosenbaum JF, Pollach MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.
268. Tollefson GD, Luxenberg M, Valentine R, Dunsmore G, Tolefson SL. An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. J Clin Psychiatry 1991;52:502-508.
269. Torres-Ruiz AT. A double-blind study of alprazolam and lorazepam in the treatment of anxiety. J Clin Psychiatry 1983;44:60-62.
270. Uhlenhuth EH, Matuzas W, Glass RM, Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989;17:261-270.
271. Uhlenhuth EH, Alexander PE, Dempsey GM, Jones W, Coleman BS, Swiontek AM. Medication side effects in anxious patients: Negative placebo responses? J Affect Disord 1998;47:183-190.
272. Väissänen E, Jalkanen E. A double-blind study of alprazolam and oxazepam in the treatment of anxiety. Acta Psychiatr Scand 1987;75:536-541.
273. Vermeeren A, Jackson JL, Muntjewerff ND, Quint PJ, Harrison EM, O'Hanlon JF. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. Psychopharmacology 1995;118:1-9.
274. Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: A randomized, placebo-controlled study. Neuropsychopharmacology 2002;27: 260-269.
275. Verster JC, Verbaten MN, Volkerts ER. Next-day residual effects of sleeping medicine on driving ability: A review of the literature. In: Lader M, Pandi-Perumal SR, Cardinali OP, Eds. Sleep and sleep disorders: A neuropsychopharmacological approach. Landes Bioscience, in press.
276. Wald TG, Kathol RG, Noyes R, Carrol BT, Clamon GH. Rapid relief of anxiety in cancer patients with both alprazolam and placebo. Psychosomatics 1993;34:324-332.
277. Weissman MM, Prusoff B, Sholomskas AJ, Greenwald S. A double-blind clinical trial of alprazolam, or placebo in the depressed elderly. J Clin Psychopharmacol 1992;12:175-182.
278. Wilcox JA. An open comparison of diazepam and alprazolam. J Psychoact Drugs 1986;18:159-160.
279. Wilhelm FH, Roth WT. Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther 1997;35:831-841.
280. Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: Preliminary results. J Clin Psychopharmacol 1991;11:48-51.
281. Wong SL, Locke C, Staser J, Granneman GR. Lack of multiple dosing effects of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology 1998;135:236-241.
282. Woodman CL, Noyes R, Ballenger JC, Lydiard RB, Sievers G, Mihalko D. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord 1994;30:5-13.
283. Wright CE, Lasher Sisson T, Fleishaker JC, Antal EJ. Pharmacokinetics and psychomotor performance of alprazolam: Concentration-effect relationship. J Clin Pharmacol 1997;37:321-329.
284. Yamadera H, Okawa M, Takahashi K. Open study of effects of alprazolam on seasonal affective disorder. Psychiatr Clin Neurosci 2001;55:27-30.
285. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vitro evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-519.
286. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 1998;139:269-273.
287. Yasui N, Kondo T, Furukori H, et al. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 2000;150: 185-190.
288. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 1997;278:983-988.
289. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, placebo-controlled crossover trial. J Clin Psychiatry 1998;59: 76-80.
290. Zamorski MA, Albucher RC. What to do when SSRIs fail: Eight strategies for optimizing treatment of panic disorder. Am Fam Physician 2002;66:1477-84.
291. Zawertailo LA, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 1995;15:117-124.